BioNTech (NASDAQ:BNTX) Rating Reiterated by HC Wainwright
BioNTech (NASDAQ:BNTX – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $113.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 40.58% from the stock’s previous close. A number of […]
More Stories
Vanguard S&P 500 ETF (NYSEARCA:VOO) Position Increased by Wealth Dimensions Group Ltd.
Wealth Dimensions Group Ltd. lifted its holdings in Vanguard S&P 500 ETF (NYSEARCA:VOO – Free Report) by 4.7% during the...
Marco Investment Management LLC Raises Position in Thermo Fisher Scientific Inc. (NYSE:TMO)
Marco Investment Management LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 3.1%...
766 Shares in S&P Global Inc. (NYSE:SPGI) Bought by Hartford Funds Management Co LLC
Hartford Funds Management Co LLC purchased a new stake in S&P Global Inc. (NYSE:SPGI – Free Report) during the 3rd...
Marco Investment Management LLC Decreases Stock Position in The Coca-Cola Company (NYSE:KO)
Marco Investment Management LLC reduced its position in The Coca-Cola Company (NYSE:KO – Free Report) by 5.2% in the third...
Marco Investment Management LLC Has $11.05 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)
Marco Investment Management LLC lifted its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 3.4%...
3M (NYSE:MMM) Shares Sold by Cahill Financial Advisors Inc.
Cahill Financial Advisors Inc. lowered its holdings in shares of 3M (NYSE:MMM – Free Report) by 2.8% in the third...